Cargando…
Venous sinus thrombosis after the first dose of Pfizer BioNTech vaccine
mRNA vaccines including Pfizer BioNTech and Moderna have categorically been considered safe when it comes to preventing COVID-19. However, there is still a small associated risk of thromboembolic phenomenon including venous sinus thrombosis with it and our case report highlights one. We describe a p...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9125703/ https://www.ncbi.nlm.nih.gov/pubmed/35606039 http://dx.doi.org/10.1136/bcr-2021-247493 |
_version_ | 1784711992974508032 |
---|---|
author | Qureshi, Muhammad Imran Ahmad Azam, Bilal Waheed, Muhammad Aamir Imran, Afsheen |
author_facet | Qureshi, Muhammad Imran Ahmad Azam, Bilal Waheed, Muhammad Aamir Imran, Afsheen |
author_sort | Qureshi, Muhammad Imran Ahmad |
collection | PubMed |
description | mRNA vaccines including Pfizer BioNTech and Moderna have categorically been considered safe when it comes to preventing COVID-19. However, there is still a small associated risk of thromboembolic phenomenon including venous sinus thrombosis with it and our case report highlights one. We describe a patient who developed severe progressive headache, tinnitus and visual disturbance symptoms post-Pfizer-SARS-CoV-2 vaccination. His medical history included essential tremors, hypertension, type 2 diabetes mellitus, chronic kidney disease stage 3, anxiety, depression and long-term catheterisation. Systemic examination revealed hypotonia, generalised reduced power and central diplopia along with peripheral visual field defect in the left eye. He was extensively investigated, the COVID-19 PCR test was negative and all routine blood tests were in the normal range except a marginally raised D-dimer of 779 ng/mL. CT head was unremarkable. He was also tested for myasthenia gravis; however, acetylcholine receptors antibodies were negative and nerve conduction studies were normal. Subsequent MRI of the brain with venography confirmed venous sinus thrombosis. A 24-hour Holter monitoring test did not reveal any cardiac rate or rhythm abnormality. He was treated with apixaban as per a neurologist’s advice. His clinical condition started to improve and was later discharged from the hospital with an outpatient neurologist clinic follow-up. |
format | Online Article Text |
id | pubmed-9125703 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-91257032022-06-04 Venous sinus thrombosis after the first dose of Pfizer BioNTech vaccine Qureshi, Muhammad Imran Ahmad Azam, Bilal Waheed, Muhammad Aamir Imran, Afsheen BMJ Case Rep Case Reports: Adverse drug reactions and complications mRNA vaccines including Pfizer BioNTech and Moderna have categorically been considered safe when it comes to preventing COVID-19. However, there is still a small associated risk of thromboembolic phenomenon including venous sinus thrombosis with it and our case report highlights one. We describe a patient who developed severe progressive headache, tinnitus and visual disturbance symptoms post-Pfizer-SARS-CoV-2 vaccination. His medical history included essential tremors, hypertension, type 2 diabetes mellitus, chronic kidney disease stage 3, anxiety, depression and long-term catheterisation. Systemic examination revealed hypotonia, generalised reduced power and central diplopia along with peripheral visual field defect in the left eye. He was extensively investigated, the COVID-19 PCR test was negative and all routine blood tests were in the normal range except a marginally raised D-dimer of 779 ng/mL. CT head was unremarkable. He was also tested for myasthenia gravis; however, acetylcholine receptors antibodies were negative and nerve conduction studies were normal. Subsequent MRI of the brain with venography confirmed venous sinus thrombosis. A 24-hour Holter monitoring test did not reveal any cardiac rate or rhythm abnormality. He was treated with apixaban as per a neurologist’s advice. His clinical condition started to improve and was later discharged from the hospital with an outpatient neurologist clinic follow-up. BMJ Publishing Group 2022-05-19 /pmc/articles/PMC9125703/ /pubmed/35606039 http://dx.doi.org/10.1136/bcr-2021-247493 Text en © BMJ Publishing Group Limited 2022. No commercial re-use. See rights and permissions. Published by BMJ. |
spellingShingle | Case Reports: Adverse drug reactions and complications Qureshi, Muhammad Imran Ahmad Azam, Bilal Waheed, Muhammad Aamir Imran, Afsheen Venous sinus thrombosis after the first dose of Pfizer BioNTech vaccine |
title | Venous sinus thrombosis after the first dose of Pfizer BioNTech vaccine |
title_full | Venous sinus thrombosis after the first dose of Pfizer BioNTech vaccine |
title_fullStr | Venous sinus thrombosis after the first dose of Pfizer BioNTech vaccine |
title_full_unstemmed | Venous sinus thrombosis after the first dose of Pfizer BioNTech vaccine |
title_short | Venous sinus thrombosis after the first dose of Pfizer BioNTech vaccine |
title_sort | venous sinus thrombosis after the first dose of pfizer biontech vaccine |
topic | Case Reports: Adverse drug reactions and complications |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9125703/ https://www.ncbi.nlm.nih.gov/pubmed/35606039 http://dx.doi.org/10.1136/bcr-2021-247493 |
work_keys_str_mv | AT qureshimuhammadimranahmad venoussinusthrombosisafterthefirstdoseofpfizerbiontechvaccine AT azambilal venoussinusthrombosisafterthefirstdoseofpfizerbiontechvaccine AT waheedmuhammadaamir venoussinusthrombosisafterthefirstdoseofpfizerbiontechvaccine AT imranafsheen venoussinusthrombosisafterthefirstdoseofpfizerbiontechvaccine |